Bringing the fundamentals into focus…
Back to C4 Therapeutics, Inc.
How C4 Therapeutics, Inc. stacks up
CCCC · against 368 other Healthcare companies of similar size
Growth
69/ 100
Above the middle of the pack.
Ranked #96 of 369 · scores higher than 73% of peers
Bars: peers in each 10-point band of the growth score32 peers with a growth score of 60–69, including CCCC · Click a bar to see the companies
Why growth scores 69?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its 3-year revenue growth, which is stronger than most Healthcare peers.
- slower revenue growth over the last year: weaker than 63% of peers. Revenue growth: 2.3% vs peer median 6.1%
- Still loss-making, but the loss per share narrowed. Earnings per share growth: — vs peer median 9.8%
- faster revenue growth over three years: stronger than 88% of peers. 3-year revenue growth: 29.8% vs peer median 5.8%
Metric by metric
Position: dot = CCCC, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | CCCC | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 383 reported | 2.3% | 2.8% | 49% | 33% | |
| Earnings per share growthHigher is better · 184 reported | Not reported | 3.8% | — | — | 33% |
| 3-year revenue growthHigher is better · 362 reported | 29.8% | 3.5% | 90% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around CCCC| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 464M USD | 100 | 53 | |
| 2 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 2 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 2 | 433M USD | 99 | 81 | |
| 2 | 609M USD | 99 | 91 | |
| 93 | 595M USD | 70 | 29 | |
| 96 | 1.6B HKD (≈$209M) | 69 | 44 | |
| 96 | 2.1B CNY (≈$293M) | 69 | 63 | |
| 96 | 3.5B CNY (≈$491M) | 69 | 79 | |
| 96 | 395M USD | 69 | 30 | |
| 96 | 14.3B TRY (≈$428M) | 69 | 60 | |
| 96 | 504M USD | 69 | 24 | |
| 102 | 585.5B KRW (≈$422M) | 68 | 63 | |
| 102 | 6.1B HKD (≈$775M) | 68 | 49 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score